GTC is hiring for several positions including Molecular CLS, hematopathologist, Molecular QA Manager, and more. Check out our careers page for more info: https://lnkd.in/d7dyafk #CLS #Pathology #Hiring
Genomic Testing Cooperative
Biotechnology Research
Lake Forest, California 2,575 followers
Making Genomics Available and Affordable for Everyone
About us
Our Mission is to create a diagnostic service that provides access to advanced genomic testing in communities everywhere. Our testing provides answers for ALL cancers covering both solid tumors and hematologic neoplasms. Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. In creating a network of Co-Op partners, we help get results to physicians faster, share knowledge and generate better outcomes for patients.
- Website
-
https://genomictestingcooperative.com
External link for Genomic Testing Cooperative
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Lake Forest, California
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Genomic testing, Precision Medicine, Next Gen Sequencing, Oncology, Hematology, Comprehensive Genomic Profiling, Leukemia, Lymphoma, Myeloma, Lung Cancer, Breast Cancer, Colon Cancer, and CDx
Locations
-
Primary
25371 Commercentre Dr
Lake Forest, California 92630, US
Employees at Genomic Testing Cooperative
-
Jeffrey Owen
Vice President, Marketing @ Genomic Testing Cooperative
-
Rachel Rosenberger
Lead Clinical Data Reporter at Genomic Testing Cooperative
-
Maher Albitar
Founder, Chief Executive Officer and Chief Medical Officer at Genomic Testing Cooperative
-
Jennifer Varca
Vice President, Business Development
Updates
-
GTC is committed to driving innovation in RNA, some highlights of this include: -T and B cell clonality via RNA -HPV, EBV and TTV via RNA -Gene expression profiling via cfRNA -Reliable fusion detection via cfRNA -Alternative splicing and exon skipping Learn more: https://lnkd.in/eEUyiVEx #RNA #Geneexpression #cfRNA #Fusions
-
BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI's global ecosystem of clinical laboratories. Read the full PR https://lnkd.in/drez2sNM #Digitalpathology #AI #NGS
-
Our Hematology Profile Plus provides: -Comprehensive and sensitive profile of mutations distinguishing between benign and malignant process -Comprehensive clonality evaluation of B- and T-cell clonality including heavy and light chains for B-cells, alpha, beta, gamma, and delta T-cell receptors with defining the expressed gene family so multiple lesions can be compared - Complete immunophenotyping profiling of the lymphoid cells (CD19, CD20, CD22, CD3, CD4, CD8, CD5, CD7, CD30, ...) - Presence or absence of EBV and HPV viruses - Complete chromosomal gain or loss and translocations Learn more: https://lnkd.in/g_Biiba #Hematology #Clonality #Immunophenotyping #RNA
-
GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it discusses ways to help save money the health care system money and be more efficient. https://lnkd.in/dPi59kGK https://lnkd.in/eiWuKegG
-
Through DNA and RNA sequencing we identified a new CAR T-cell construct that caused CD4+ CAR T-Cell lymphoma in a patient previously treated with Cilta-cel CAR T-Cell Therapy for multiple myeloma. This is a unique capability of GTC’s testing. GTC’s NEJM publication resulting from collaborative efforts with our partners: Dana-Farber Cancer Institute/Harvard Medical School, Georgetown University, Brigham and Women’s Hospital, and the National Institute of Medicine. Learn more: https://lnkd.in/dzQZPXKF This publication highlights our commitment to advancing genomics and precision medicine through strong collaborations and innovative research. #Lymphoma #NEJM #RNA
-
In honor of Sarcoma Awareness Month GTC would like to highlight the importance of RNA testing since gene fusions are one of dominate abnormalities in these tumors like the EWSR1. Learn more about RNA testing: https://lnkd.in/d8NzX7b #Sarcomaawarenessmonth #Ewingsarcoma #Sarcoma
-
A comprehensive molecular evaluation will help you identify both common and rare abnormalities you may not routinely test for in traditional pathology workups. Running one comprehensive test may also be more cost-effective than traditional approaches. Learn more: https://lnkd.in/gBmGD6u #RNA #NGS #CGP
-
Quantify your detected mutations with Liquid Trace GTC's Liquid Trace reports now include a graphic presentation of the detected mutations as quantified per 1 mL of plasma or CSF. Learn more: https://lnkd.in/duiFUP8F #CSF #Liquidbiopsy #cfRNA